Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Effect of obesity on susceptibility to fatty acid-induced peripheral tissue insulin resistance.

Kruszynska YT, Olefsky JM, Frias JP.

Metabolism. 2003 Feb;52(2):233-8.

PMID:
12601639
2.

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.

Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM.

Diabetes. 2002 Oct;51(10):2968-74.

3.

Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation.

Kruszynska YT, Worrall DS, Ofrecio J, Frias JP, Macaraeg G, Olefsky JM.

J Clin Endocrinol Metab. 2002 Jan;87(1):226-34.

PMID:
11788651
4.

Decreased susceptibility to fatty acid-induced peripheral tissue insulin resistance in women.

Frias JP, Macaraeg GB, Ofrecio J, Yu JG, Olefsky JM, Kruszynska YT.

Diabetes. 2001 Jun;50(6):1344-50.

6.

Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.

Frias JP, Yu JG, Kruszynska YT, Olefsky JM.

Diabetes Care. 2000 Jan;23(1):64-9.

7.

Lack of effect of a physiological elevation of plasma non-esterified fatty acid levels on insulin secretion.

Frias JP, Basabe L, Macaraeg G, Kruszynska YT.

Diabetes Metab. 2000 Apr;26(2):133-9.

PMID:
10804328
8.

Effects of insulin on prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia.

Draznin B, Miles P, Kruszynska Y, Olefsky J, Friedman J, Golovchenko I, Stjernholm R, Wall K, Reitman M, Accili D, Cooksey R, McClain D, Goalstone M.

Endocrinology. 2000 Apr;141(4):1310-6.

PMID:
10746633
9.
10.

Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects.

Kruszynska YT, Mulford MI, Baloga J, Yu JG, Olefsky JM.

Diabetes. 1998 Jul;47(7):1107-13.

PMID:
9648835
11.
12.

Skeletal muscle peroxisome proliferator- activated receptor-gamma expression in obesity and non- insulin-dependent diabetes mellitus.

Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti JR, Olefsky JM.

J Clin Invest. 1998 Feb 1;101(3):543-8.

13.

Effects of nonesterified fatty acids on glucose metabolism after glucose ingestion.

Kruszynska YT, Mulford MI, Yu JG, Armstrong DA, Olefsky JM.

Diabetes. 1997 Oct;46(10):1586-93.

PMID:
9313754
14.

Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus.

Kruszynska YT, Olefsky JM.

J Investig Med. 1996 Oct;44(8):413-28. Review. No abstract available.

PMID:
8952222
15.

Acute effects of central neuropeptide Y injection on glucose metabolism in fasted rats.

Wilding IP, Kruszynska YT, Lambert PD, Bloom SR.

Clin Sci (Lond). 1995 Nov;89(5):543-8.

PMID:
8549070
16.
17.

The contribution of proinsulin and des-31,32 proinsulin to the hyperinsulinemia of diabetic and nondiabetic cirrhotic patients.

Kruszynska YT, Harry DS, Mohamed-Ali V, Home PD, Yudkin JS, McIntyre N.

Metabolism. 1995 Feb;44(2):254-60.

PMID:
7869924
18.

Lipid metabolism and substrate oxidation during intravenous fructose administration in cirrhosis.

Kruszynska YT, Harry DS, Fryer LG, McIntyre N.

Metabolism. 1994 Sep;43(9):1171-81.

PMID:
8084292
19.

Lipid metabolism and insulin resistance in cirrhosis.

Kaye GL, Kruszynska YT, Harry DS, Heslop K, Johnston DG, McIntyre N.

J Hepatol. 1994 Jun;20(6):782-91.

PMID:
7930479
20.

Energy expenditure and substrate metabolism after oral fructose in patients with cirrhosis.

Kruszynska YT, Meyer-Alber A, Wollen N, McIntyre N.

J Hepatol. 1993 Sep;19(2):241-51.

PMID:
8301057

Supplemental Content

Loading ...
Support Center